Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab.
Shijie ZhouFilipe CirneJustin Y ChowArman ZereshkianLouise BordeleauSukhbinder Dhesy-ThindPeter M EllisSom D MukherjeeNazanin AghelDarryl P LeongPublished in: The oncologist (2023)
Among patients exposed to permissive trastuzumab cardiotoxicity for HER2-positive breast cancer, 6% were unable to complete planned trastuzumab due to severe LV dysfunction or clinical HF. Although most patients recover their LV function after trastuzumab discontinuation or completion, 14% still have persistent cardiotoxicity by 3-year follow-up.